Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIVGP-BCG in HIV (+) Patients
NCT07182838Phase 1Active, not recruiting
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VaxSyn HIV-1 and bcg vaccine in human immunodeficiency virus infection (HIV). Primary endpoints: Number of HIV (+) Participants at 4 weeks, Rate of Positive HIV nucleic acid at 4 weeks and 3 more. Started Oct 2026; status: active, not recruiting.
02
Drugs
VaxSyn HIV-1bcg vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07182838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182838.